A Study of Paclitaxel, Carboplatin, and Bortezomib in the Treatment of Metastatic Malignant Melanoma: A Phase 2 Consortium StudyCROGHAN, Gary A; SUMAN, Vera J; MAPLES, William J et al.Cancer. 2010, Vol 116, Num 14, pp 3463-3468, issn 0008-543X, 6 p.Article

Tobacco use outcomes among patients with lung cancer treated for nicotine dependenceCOX, Lisa Sanderson; PATTEN, Christi A; EBBERT, Jon O et al.Journal of clinical oncology. 2002, Vol 20, Num 16, pp 3461-3469, issn 0732-183XArticle

A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignanciesMA, Cynthia; MANDREKAR, Sumithra J; ERIICHMAN, Charles et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 2, pp 207-215, issn 0344-5704, 9 p.Article

Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trialBURCH, Patrick A; CROGHAN, Gary A; GASTINEAU, Dennis A et al.The Prostate. 2004, Vol 60, Num 3, pp 197-204, issn 0270-4137, 8 p.Article

A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancerADJEI, Alex A; CROGHAN, Gary A; BRUZEK, Laura M et al.Clinical cancer research. 2003, Vol 9, Num 7, pp 2520-2526, issn 1078-0432, 7 p.Article

Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhalerHURT, Richard D; CROGHAN, Gary A; WOLTER, Troy D et al.Nicotine & tobacco research. 2000, Vol 2, Num 4, pp 327-336, issn 1462-2203Article

Combination of paclitaxel and carboplatin as second- line therapy for patients with metastatic melanomaRAO, Ravi D; HOLTAN, Shernan G; INGLE, James N et al.Cancer. 2006, Vol 106, Num 2, pp 375-382, issn 0008-543X, 8 p.Article

A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in Patients with advanced CancerDY, Grace K; BRUZEK, Laura M; CHENG, Shinta et al.Clinical cancer research. 2005, Vol 11, Num 5, pp 1877-1883, issn 1078-0432, 7 p.Article

Tobacco use outcomes among patients with head and neck carcinoma treated for nicotine dependence: A matched-pair analysisGARCES, Yolanda I; SCHROEDER, Darrell R; NIRELLI, Liza M et al.Cancer. 2004, Vol 101, Num 1, pp 116-124, issn 0008-543X, 9 p.Article

Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusionsLIESER, Elizabeth Ann T; CROGHAN, Gary A; NEVALA, Wendy K et al.Lung cancer. 2013, Vol 82, Num 1, pp 63-68, issn 0169-5002, 6 p.Article

Genetic Variations in Multiple Drug Action Pathways and Survival in Advanced Stage Non―Small Cell Lung Cancer Treated with ChemotherapyYAFEI LI; ZHIFU SUN; LIEWEI WANG et al.Clinical cancer research (Print). 2011, Vol 17, Num 11, pp 3830-3840, issn 1078-0432, 11 p.Article

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse preventionCROGHAN, Ivana T; HURT, Richard D; TSCHETTER, Loren K et al.Mayo Clinic proceedings. 2007, Vol 82, Num 2, pp 186-195, issn 0025-6196, 10 p.Article

Effects of biochemically confirmed smoking cessation on white blood cell countABEL, Gregory A; HAYS, J. Taylor; DECKER, Paul A et al.Mayo Clinic proceedings. 2005, Vol 80, Num 8, pp 1022-1028, issn 0025-6196, 7 p.Article

Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized settingCROGHAN, Gary A; SLOAN, Jeff A; WIESENFELD, Martin et al.Nicotine & tobacco research. 2003, Vol 5, Num 2, pp 181-187, issn 1462-2203, 7 p.Article